Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Wave Life Sciences Q3 revenue jumps, beats estimates

By Reuters News


Overview

  • Biotechnology firm's Q3 revenue rose and beat analyst expectations

  • Company reported smaller-than-expected pretax and net loss figures

  • Company advanced clinical pipeline, including planning registrational trial for WVE-006 in AATD


Outlook

  • Company expects cash runway to fund operations into Q3 2028

  • Wave plans to initiate WVE-007 post-incretin maintenance trial in Q4 2026

  • Company plans registrational trial for WVE-006 in AATD with interim analysis for accelerated approval


Result Drivers

  • HIGHER REVENUE FROM COLLABORATION - Co said Q3 revenue increase was primarily due to a $12 mln milestone payment earned from GSK for candidate selection in their collaboration program

  • INCREASED R&D SPENDING - Co reported higher research and development expenses in Q3, reflecting advancement of lead clinical programs including WVE-006 and WVE-007


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$13.16 mln

$4.32 mln (18 Analysts)

Q3 Loss Per Share

$0.30

Q3 Net Loss

Beat

$61.91 mln

$67.83 mln (17 Analysts)

Q3 Income from Operations

Beat

-$66.05 mln

-$70.53 mln (17 Analysts)

Q3 Pretax Loss

Beat

$61.91 mln

$67.65 mln (14 Analysts)

Q3 Operating Expenses

$79.21 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Wave Life Sciences, Inc. is $15.00, about 367.3% above its October 26 closing price of $3.21


Reuters Recommended Reads

  • Oct 26 - GSK, Hansoh's bone cancer drug delays disease progression in late-stage China study

  • Oct 26 - Aspen Neuroscience, Bambusa Therapeutics launch US IPOs as biotech boom rolls on

  • Oct 27 - Novartis slightly misses Q3 net sales estimates, but tops core EPS view


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.